Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL732127 | 0.98 | NT5E (0.49) | NT5ESLC22A12SMN1; SMN2NCF1KDM4E | |
| SCHEMBL29403274 | 0.84 | ALK (0.50) | NT5ESLC22A12SMN1; SMN2NCF1KDM4E | |
| SCHEMBL1809544 | 0.84 | ALK (0.50) | NT5ESLC22A12SMN1; SMN2NCF1KDM4E | |
| SCHEMBL1888577 | 0.79 | NR4A2 (0.66) | MEN1KMT2AALDH1A1L3MBTL1CCNC | |
| SCHEMBL30051309 | 0.79 | NR4A2 (0.66) | MEN1KMT2AALDH1A1L3MBTL1CCNC | |
| SCHEMBL29896761 | 0.79 | SLC22A12 (0.51) | SLC22A12SMN1; SMN2NCF1LMNAALDH1A1 | |
| SCHEMBL14690611 | 0.79 | SLC22A12 (0.51) | SLC22A12SMN1; SMN2NCF1LMNAALDH1A1 | |
| SCHEMBL20392628 | 0.77 | SLC22A12 (0.46) | SLC22A12SMN1; SMN2NCF1KDM4EMEN1 | |
| SCHEMBL599869 | 0.76 | DYRK1B (0.47) | SMN1; SMN2KDM4EMEN1KMT2ALMNA | |
| SCHEMBL6162407 | 0.76 | ESR1 (0.50) | KDM4EMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868049-B | Process for preparing somatostatin modulators | 克林提克斯医药股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| EP-3740475-B1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | CRINETICS PHARMACEUTICALS INC (US) | 2022-04-20 | — | — | EP | claimed |
| US-20210087165-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2021-03-25 | — | — | US | claimed |
| EP-3740475-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | claimed |
| CN-111868049-A | Methods of making somatostatin modulators | 克林提克斯医药股份有限公司 | 2020-10-30 | — | — | CN | claimed |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2020-02-13 | — | — | US | claimed |
| US-10464918-B2 | Process of making somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | claimed |
| WO-2019143718-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. (US) | 2019-07-25 | — | — | WO | claimed |
| US-20190218202-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2019-07-18 | — | — | US | claimed |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-12617767-B2 | Crystalline forms of somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260070899-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| WO-2005120509-A1 | QUINOLINE- AND ISOQUINOLINE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| CN-1662521-A | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2005-08-31 | — | — | CN | disclosed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464918-B2 | Process of making somatostatin modulators | SSTR5, SSTR4, SSTR2 | NT5E 1475/4885SLC22A12 4029/4885SMN1; SMN2 869/4885 |
| US-12617767-B2 | Crystalline forms of somatostatin modulators | IAPP, SSTR2, SSTR3 | NT5E 3963/4885SLC22A12 2941/4885SMN1; SMN2 2142/4885 |
| US-20190218202-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | NT5E 1475/4885SLC22A12 4029/4885SMN1; SMN2 869/4885 |
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | NT5E 4334/4885SLC22A12 878/4885SMN1; SMN2 960/4885 |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | RIPK1, RIPK2, RIPK4 | NT5E 2312/4885SLC22A12 4782/4885SMN1; SMN2 1758/4885 |
| US-20210087165-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | NT5E 1475/4885SLC22A12 4029/4885SMN1; SMN2 869/4885 |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | NT5E 1475/4885SLC22A12 4029/4885SMN1; SMN2 869/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | NT5E 3777/4885SLC22A12 4697/4885SMN1; SMN2 4444/4885 |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | NT5E 2627/4885SLC22A12 1315/4885SMN1; SMN2 1842/4885 |
| US-20260070899-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, CTRL, CTSC | NT5E 1851/4885SLC22A12 3711/4885SMN1; SMN2 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.